eyeforpharma Barcelona Conference, Expo & Awards 2019

eyeforpharma12 - 14 March 2019, Barcelona, Spain.
It's 2019, and it's time for something new. Attendance is ahead of expectations, eyeforpharma Barcelona is on track for over 1300 pharma decision makers from Sales, Marketing, Patient Engagement, Patient Advocacy, Medical Affairs, Digital, Market Access and RWE functions to fuse with health innovators, payers, patients, start-ups and cutting-edge tech.

On current projections, tickets will sell out this year. Ensure you have a place reserved at the only meeting where executives forge a new future for the pharma industry.

Medicine is just the beginning

Medicines are essential, yet they're rarely the entire solution. As we shift focus to outcomes, we need to be prepared to deliver value in whatever form is best for patients. The keynote sessions at eyeforpharma Barcelona will cover:
  • Value, driven.
    Change your mindset to reach beyond the incremental - and find bold solutions for real patients. Only then will outcomes be transformed.
  • Authenticity rules.
    Use greater patient insights to build trust with customers and fight for the best patient journey. Make education and credibility your mantra!
  • Tech is fundamental.
    See how digital ML & AI are delivering the data that rewrites your business plan, sets new standards and makes the connected future a reality.
  • Welcome new customers.
    Exceed elevated expectations by aligning to consumerisation - and setting new goals in wellbeing, prevention and regeneration.

New for 2019

The Innovation Stage

A showcase of bleeding-edge, industry-transforming science and new ideas which will open your eyes to the coming disruptions.

Real-World Evidence Europe Summit

For 2019 we've added our industry-leading Real-World Evidence Summit to the event to show the role RWE will play in the shift to value

The im-patient conference

Patient-focused conferences are usually designed by pharma. Until now! This time, patients have created the agenda and line-up.

Market Access Europe Summit

Market Access is vital for pharma's commercial success - that's why for 2019 it has been added as a key topic.

This is the world's biggest commercial pharma meeting and your opportunity to join 1300+ pharma leaders focused Sales, Marketing, Patient Engagement, Market Access, Medical Affairs and Real-World Evidence

World Pharma News readers can benefit from an exclusive discount, just use the code WPN300 to save €300 when you register here

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma

Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Novartis signs initial agreement to reserve capaci…

Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (...

Pfizer acquires Amplyx Pharmaceuticals

Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilita...

Moderna announces additional investments to increa…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it is making new funding commitments to i...

Moderna announces emergency use listing granted by…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the World Health Organization (WHO) has is...

Sanofi to help manufacture Moderna COVID-19 vaccin…

Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna's COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine suppl...

Valneva switches focus to bilateral discussions to…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Speeding new treatments

A year into the COVID-19 pandemic, mass vaccinations have begun to raise the tantalizing prospect of herd immunity that eventually curtails or halts the spread of SARS-Co...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the 2...

Brazilian coronavirus variant likely to be more tr…

Even though more and more vaccines against the coronavirus are being administered all over the world, many countries are still battling with outbreaks and face difficulti...

Patients who are obese or overweight are at risk f…

COVID-19 patients who are overweight or obese are more likely to develop a more severe infection than patients of healthy weight, and they require oxygen and invasive mec...

Updated results on coronavirus vaccination effecti…

Several weeks following the publication of the large real-world COVID-19 vaccine effectiveness study by the Clalit Research Institute in Collaboration with Harvard Univer...

Our immune systems blanket the SARS-CoV-2 spike pr…

The most complete picture yet is coming into focus of how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus resp...